-
Fresenius Kabi has launched into
#biosimilars to provide greater access to important medicines in the fields of autoimmune diseases and oncology. Find out more
https://fal.cn/36dNu
#freseniuskabi#caringforlifepic.twitter.com/WdJxc2KBx3
-
#FDA and#FTC announce public workshop for March 9, 2020, on a Competitive Marketplace for#Biosimilars - http://ow.ly/JQYh50ybUmM -
#FDA#FTC March 9 workshop: Food and Drug Administration/Federal Trade Commission Workshop on a Competitive Marketplace for Biosimilars https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-02101.pdf …#biosimilars#biosimilar#pharma#biotech#BPCIAPrikaži ovu nit -
#FDA guidance notice: Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products--Questions and Answers https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-02100.pdf …#biosimilars#biosimilar#pharma#biotechPrikaži ovu nit -
5 years of
#biosimilars in the US: what have we learned? https://bit.ly/37MLB25 pic.twitter.com/UPIPIteJhy
-
#Biosimilars offer an opportunity to help reduce total biologic drug spend. They could save between $54 to $250 bn over their first 10 years on the market. According to a recent estimate, there are more than 1000 biosimilars in any stage of the pipeline https://www.pharmacytimes.com/news/overview-of-the-biosimilar-landscape … -
Experts in the field of
#biosimilars wrap up their discussion by considering what must be done to educate pharmacists, nurses, and patients. https://bit.ly/37v60Ix -
From proposed stakeholder incentives in U.S. policy to the improvement of competition in the oncology space, 2019 was an eventful year for
#biosimilars. https://www.biosimilardevelopment.com/doc/the-top-biosimilar-developments-of-0001 … Via@AnnaRoseWelchpic.twitter.com/7fB4SGJEMi
-
With the sales growth seen so far and the likely addition of a Remicade biosimilar, Bernstein analyst Ronny Gal said "it's tough to see " Amgen 2020 biosimilar sales of less than $1.8 billion, up from $570 million in 2019.
#biosimilars https://www.biopharmadive.com/news/amgen-pfizer-biosimilar-growth-herceptin-avastin/571502/ … -
How much does your state save? In 2018, generic prescription medicines saved
#Idaho $1.3B, and $293B for the U.S. health care system overall. Use this interactive map to see how much your state saved: https://rxsavingsmap.org/#GRxBiosimsSavingsReport#generics#biosimilars pic.twitter.com/NBCT8trGZM
-
Will
#biosimilars ever catch on in the#US?https://bit.ly/37MhWpp -
Uptake of TNFi
#biosimilars in rheumatology has been slow. http://ms.spr.ly/6010TZkvA pic.twitter.com/50xEAcWjCX
-
According to a report by
@ODPRN_Research, by 2021, Ontario's biologics expenditure will likely increase to $1.4 billion for an estimated 564,672 users. See the full report here https://odprn.ca/wp-content/uploads/2020/01/Utilization-of-Innovator-Biologics-and-Biosimilars-in-Ontario.pdf …#biosimilars -
Kashyap Patel, MD says that
#biosimilars’ safety and efficacy have already been established--what is needed is intensive education in the U.S. https://www.fiercepharma.com/pharma/education-and-strategy-are-key-to-nurturing-biosimilars-for-success … -
With an average cost of 26% less than their reference products,
#biosimilars could provide up to $150B in savings over the next decade, notes @USBiosimilar President Juliana Reed in a recent op-ed. Read more: http://bit.ly/2srsY46 pic.twitter.com/aJvALWgvrO
-
The other concern is would as many head-to-head studies be conducted on
#biosimilars? As an#IBD patient, that’s a huge concern of mine. I would want those studies to help push forward into the era of precision medicine. -
#FebruaryIssue |#YearInReview on#biosimilars Studies in 2019 support the effectiveness and safety of nonmedical switching and the benefits of communicating information about biosimilars to patients in a positive light.@RheumKay Check it out at https://go.nature.com/3aSwwO7 pic.twitter.com/wN75TMoQLe
-
#Biosimilars have struggled to gain traction in the U.S. despite widespread adoption in Europe. Experts take recent successful launches as a positive sign for the biosimilar market overall in 2020. More: http://bit.ly/38qapfT -
Chip Davis, President & CEO of
@AccessibleMeds sees "fearmongering about the quality of biosimilars" perception and lobbying efforts as reasons for slow uptake in the U.S. By enacting incentives for#biosimilars, usage will increase. http://bit.ly/30R80IV
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.